Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet

The present study assessed the potential of the sodium glucose-linked transporter (SGLT)-2 inhibitor empagliflozin to decrease body weight when administered alone or in combination with the clinically effective weight-loss agents orlistat and sibutramine in obese rats fed a cafeteria diet. Female Wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Vickers, Steven P, Cheetham, Sharon C, Headland, Katie R, Dickinson, Keith, Grempler, Rolf, Mayoux, Eric, Mark, Michael, Klein, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085306/
https://www.ncbi.nlm.nih.gov/pubmed/25061325
http://dx.doi.org/10.2147/DMSO.S58786

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085306/
https://www.ncbi.nlm.nih.gov/pubmed/25061325
http://dx.doi.org/10.2147/DMSO.S58786

Ejemplares similares